|
1
|
Lepage C, Bouvier AM, Phelip JM, Hatem C,
Vernet C and Faivre J: Incidence and management of malignant
digestive endocrine tumours in a well defined French population.
Gut. 53:549–553. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Modlin IM, Oberg K, Chung DC, Jensen RT,
de Herder WW, Thakker RV, Caplin M, Fave G Delle, Kaltsas GA,
Krenning EP, et al: Gastroenteropancreatic neuroendocrine tumours.
Lancet Oncol. 9:61–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vélayoudom-Céphise FL, Duvillard P, Foucan
L, Hadoux J, Chougnet CN, Leboulleux S, Malka D, Guigay J, Goere D,
Debaere T, et al: Are G3 ENETS neuroendocrine neoplasms
heterogeneous? Endocr Relat Cancer. 20:649–657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zappa M, Abdel-Rehim M, Hentic O,
Vullierme MP, Ruszniewski P and Vilgrain V: Liver-directed
therapies in liver metastases from neuroendocrine tumors of the
gastrointestinal tract. Target Oncol. 7:107–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pavel M, Baudin E, Couvelard A, Krenning
E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B and Salazar R:
Barcelona Consensus Conference participants: ENETS Consensus
Guidelines for the management of patients with liver and other
distant metastases from neuroendocrine neoplasms of foregut,
midgut, hindgut, and unknown primary. Neuroendocrinology.
95:157–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maire F, Lombard-Bohas C, O'Toole D,
Vullierme MP, Rebours V, Couvelard A, Pelletier AL, Zappa M,
Pilleul F, Hentic O, et al: Hepatic arterial embolization versus
chemoembolization in the treatment of liver metastases from
well-differentiated midgut endocrine tumors: A prospective
randomized study. Neuroendocrinology. 96:294–300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rinke A, Müller HH, Schade-Brittinger C,
Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker
M, et al: Placebo-controlled, double-blind, prospective, randomized
study on the effect of octreotide LAR in the control of tumor
growth in patients with metastatic neuroendocrine midgut tumors: A
report from the PROMID Study Group. J Clin Oncol. 27:4656–4663.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Caplin ME, Pavel M, Ćwikła JB, Phan AT,
Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L,
et al: Lanreotide in metastatic enteropancreatic neuroendocrine
tumors. N Engl J Med. 371:224–233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pavel ME, Hainsworth JD, Baudin E, Peeters
M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM,
et al: Everolimus plus octreotide long-acting repeatable for the
treatment of advanced neuroendocrine tumours associated with
carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled,
phase 3 study. Lancet. 378:2005–2012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yao JC, Shah MH, Ito T, Bohas CL, Wolin
EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG,
et al: Everolimus for advanced pancreatic neuroendocrine tumors. N
Engl J Med. 364:514–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raymond E, Dahan L, Raoul JL, Bang YJ,
Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A,
et al: Sunitinib malate for the treatment of pancreatic
neuroendocrine tumors. N Engl J Med. 364:501–513. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Waldherr C, Pless M, Maecke HR, Haldemann
A and Mueller-Brand J: The clinical value of
[90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of
neuroendocrine tumours: A clinical phase II study. Ann Oncol.
12:941–945. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Imhof A, Brunner P, Marincek N, Briel M,
Schindler C, Rasch H, Mäcke HR, Rochlitz C, Müller-Brand J and
Walter MA: Response, survival, and long-term toxicity after therapy
with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in
metastasized neuroendocrine cancers. J Clin Oncol. 29:2416–2423.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Öberg K, Knigge U, Kwekkeboom D and Perren
A: ESMO Guidelines Working Group: Neuroendocrine
gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 23:(Suppl 7).
vii124–vii130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moertel CG, Hanley JA and Johnson LA:
Streptozocin alone compared with streptozocin plus fluorouracil in
the treatment of advanced islet-cell carcinoma. N Engl J Med.
303:1189–1194. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun W, Lipsitz S, Catalano P, Mailliard JA
and Haller DG: Eastern Cooperative Oncology Group: Phase II/III
study of doxorubicin with fluorouracil compared with streptozocin
with fluorouracil or dacarbazine in the treatment of advanced
carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J
Clin Oncol. 23:4897–4904. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Crona J, Fanola I, Lindholm DP,
Antonodimitrakis P, Öberg K, Eriksson B and Granberg D: Effect of
temozolomide in patients with metastatic bronchial carcinoids.
Neuroendocrinology. 98:151–155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 18:2938–2947. 2000.PubMed/NCBI
|
|
19
|
Louvet C, Labianca R, Hammel P, Lledo G,
Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, et
al: Gemcitabine in combination with oxaliplatin compared with
gemcitabine alone in locally advanced or metastatic pancreatic
cancer: Results of a GERCOR and GISCAD phase III trial. J Clin
Oncol. 23:3509–3516. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR:
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom: Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
André T, Tournigand C, Rosmorduc O,
Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun
L, Houry S, et al: Gemcitabine combined with oxaliplatin (GEMOX) in
advanced biliary tract adenocarcinoma: A GERCOR study. Ann Oncol.
15:1339–1343. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tetzlaff ED and Ajani JA:
Oxaliplatin-based chemotherapy for the treatment of a metastatic
carcinoid tumor. Int J Gastrointest Cancer. 36:55–58. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bajetta E, Catena L, Procopio G, De Dosso
S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E,
Formisano B and Bajetta R: Are capecitabine and oxaliplatin (XELOX)
suitable treatments for progressing low-grade and high-grade
neuroendocrine tumours? Cancer Chemother Pharmacol. 59:637–642.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chibaudel B, Tournigand C, Bonnetain F,
Maindrault-Goebel F, Lledo G, André T, Larsen AK, Bengrine-Lefevre
L, Louvet C and de Gramont A: Platinum-sensitivity in metastatic
colorectal cancer: Towards a definition. Eur J Cancer.
49:3813–3820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moertel CG, Lefkopoulo M, Lipsitz S, Hahn
RG and Klaassen D: Streptozocin-doxorubicin,
streptozocin-fluorouracil or chlorozotocin in the treatment of
advanced islet-cell carcinoma. N Engl J Med. 326:519–523. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dahan L, Bonnetain F, Rougier P, Raoul JL,
Gamelin E, Etienne PL, Cadiot G, Mitry E, Smith D, Cvitkovic F, et
al: Phase III trial of chemotherapy using 5-fluorouracil and
streptozotocin compared with interferon alpha for advanced
carcinoid tumors: FNCLCC FFCD 9710. Endocr Relat Cancer.
16:1351–1361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kouvaraki MA, Ajani JA, Hoff P, Wolff R,
Evans DB, Lozano R and Yao JC: Fluorouracil, doxorubicin, and
streptozocin in the treatment of patients with locally advanced and
metastatic pancreatic endocrine carcinomas. J Clin Oncol.
22:4762–4771. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cassier PA, Walter T, Eymard B, Ardisson
P, Perol M, Paillet C, Chayvialle JA, Scoazec JY, Hervieu V and
Bohas CL: Gemcitabine and oxaliplatin combination chemotherapy for
metastatic well-differentiated neuroendocrine carcinomas: A
single-center experience. Cancer. 115:3392–3399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kulke MH, Hornick JL, Frauenhoffer C,
Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart
K, Fuchs CS and Redston MS: O6-methylguanine DNA methyltransferase
deficiency and response to temozolomide-based therapy in patients
with neuroendocrine tumors. Clin Cancer Res. 15:338–345. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ekeblad S, Sundin A, Janson ET, Welin S,
Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd
M, et al: Temozolomide as monotherapy is effective in treatment of
advanced malignant neuroendocrine tumors. Clin Cancer Res.
13:2986–2991. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ducreux M, Dahan L, Smith D, O'Toole D,
Lepère C, Dromain C, Vilgrain V, Baudin E, Lombard-Bohas C, Scoazec
JY, et al: Bevacizumab combined with 5-FU/streptozocin in patients
with progressive metastatic well-differentiated pancreatic
endocrine tumours (BETTER trial)-a phase II non-randomised trial.
Eur J Cancer. 50:3098–3106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mitry E, Walter T, Baudin E, Kurtz JE,
Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G,
Dromain C, Farace F, et al: Bevacizumab plus capecitabine in
patients with progressive advanced well-differentiated
neuroendocrine tumors of the gastro-intestinal (GI NETs) tract
(BETTER trial)-a phase II non-randomised trial. Eur J Cancer.
50:3107–3115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rinke A, Müller H-H, Schade-Brittinger C,
Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker
M, et al: Placebo-controlled, double-blind, prospective, randomized
study on the effect of octreotide LAR in the control of tumor
growth in patients with metastatic neuroendocrine midgut tumors: A
report from the PROMID Study Group. J Clin Oncol. 27:4656–4663.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bajetta E, Zilembo N, Di Bartolomeo M, Di
Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L,
Dogliotti L, et al: Treatment of metastatic carcinoids and other
neuroendocrine tumors with recombinant interferon-alpha-2a. A study
by the Italian Trials in Medical Oncology Group. Cancer.
72:3099–3105. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chu E: Bevacizumab targeted therapy:
Validation of angiogenesis as a key target for advanced colorectal
cancer. Clin Colorectal Cancer. 4:162004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tabernero J, Van Cutsem E, Lakomý R,
Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR,
McKendrick JJ, Soussan-Lazard K, et al: Aflibercept versus placebo
in combination with fluorouracil, leucovorin and irinotecan in the
treatment of previously treated metastatic colorectal cancer:
Prespecified subgroup analyses from the VELOUR trial. Eur J Cancer.
50:320–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yao JC, Phan A, Hoff PM, Chen HX,
Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL and Ajani
JA: Targeting vascular endothelial growth factor in advanced
carcinoid tumor: A random assignment phase II study of depot
octreotide with bevacizumab and pegylated interferon alpha-2b. J
Clin Oncol. 26:1316–1323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chan JA, Stuart K, Earle CC, Clark JW,
Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA,
Zheng H, et al: Prospective study of bevacizumab plus temozolomide
in patients with advanced neuroendocrine tumors. J Clin Oncol.
30:2963–2968. 2012. View Article : Google Scholar : PubMed/NCBI
|
